Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes

Cardiovascular Research

Volumn 102, Issue 3, 2014, Pages 497-506

  Mehta, Ashish ^a,b   Sequiera, Glen Lester ^a   Ramachandra, Chrishan J A ^a   Sudibyo, Yuliansa ^a   Chung, Yingying ^a   Sheng, Jingwei ^a   Wong, Keng Yean ^c   Tan, Teng Hong ^c   Wong, Philip ^a,d   Liew, Reginald ^a,d   Shim, Winston ^a,b,d  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b National Heart Research Institute Singapore   (Singapore)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cardiomyocytes; Induced pluripotent stem cells; Ion channels; Long QT syndrome; Trafficking

Indexed keywords

CHAPERONE; N [N (N ACETYLLEUCYL)LEUCYL]NORLEUCINE; NORLEUCINE; POTASSIUM CHANNEL HERG; PROTEASOME; UNCLASSIFIED DRUG; ACETYLLEUCYL-LEUCYL-NORLEUCINAL; ERG1 POTASSIUM CHANNEL; LEUPEPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GLYCOSYLATION; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; LONG QT SYNDROME 2; MISSENSE MUTATION; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROCESSING; ANIMAL; CYTOLOGY; GENETICS; LONG QT SYNDROME; MALE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT;

ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUPEPTINS; LONG QT SYNDROME; MALE; MICE; MUTATION; MYOCYTES, CARDIAC; PHENOTYPE; PROTEIN TRANSPORT;

EID: 84901452339     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu060     Document Type: Article

References (36)

1. Keating MT, Sanguinetti MC. Pathophysiology of ion channel mutations. Curr Opin Genet Dev 1996;6: 326-333.
2. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med 2008;358: 169-176.
3. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol 2008;51: 2291-2300.
4. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32: 952-962.
5. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52: 557-594.
6. Thomas D, Kiehn J, Katus HA, Karle CA. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): Molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 2003;60: 235-241.
7. Bellocq C, Wilders R, Schott JJ, Louerat-Oriou B, Boisseau P, Le Marec H, Escande D, Baro I. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol 2004;66: 1093-1102.
8. Ficker E, Dennis AT, Obejero-Paz CA, Castaldo P, Taglialatela M, Brown AM. Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome. J Mol Cell Cardiol 2000;32: 2327-2337.
9. Kagan A, Yu Z, Fishman GI, McDonald TV. The dominant negative LQT2 mutation A561V reduces wild-type HERG expression. J Biol Chem 2000;275: 11241-11248.
10. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. Modelling the longQT syndrome with induced pluripotent stem cells. Nature 2011;471: 225-229.
11. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL. Patientspecific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363: 1397-1409.
12. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324: 797-801.
13. Mehta A, ChungYY, NgA, Iskandar F, Atan S, WeiH, Dusting G, SunW, Wong P, Shim W. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc Res 2011;91: 577-586.
14. Ritner C, Bernstein HS. Fate mapping of human embryonic stem cells by teratoma formation. J Vis Exp 2010;42: E2036.
15. Mehta A, Chung YY, Sequiera GL, Wong P, Liew R, Shim W. Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. Toxicol Sci 2013;131: 458-469.
16. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009;120: 1513-1523.
17. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440: 463-469.
18. Patel C, Antzelevitch C. Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther 2008;118: 138-151.
19. Beckmann JS, Spencer M. Calpain 3, the 'gatekeeper' of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 2008;18: 913-921.
20. Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovasc Res 2012; 96: 32-37.
21. Guo J, Wang T, Li X, Shallow H, Yang T, LiW, Xu J, Fridman MD, Yang X, Zhang S. Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2. J Biol Chem 2012;287: 33132-33141.
22. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: Clinical impact. Circulation 1999;99: 529-533.
23. Napolitano C, Priori SG, Schwartz PJ, Timothy K, Paganini V, Cantú F, Bloise R, De Fusco M, Spazzolini C, Casari G. Identification of amutational hot spot in HERG-related longQTsyndrome (LQT2): Phenotypic implications. Circulation 1997;96(Suppl I): I-212.
24. Priori SG, Barhanin J, Hauer RN, HaverkampW, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II. Circulation 1999;99: 518-528.
25. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, Gong Q, Zhou Z, Ackerman MJ, January CT. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 2006;113: 365-373.
26. Ficker E, Dennis AT, Wang L, Brown AM. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003;92: E87-100.
27. Schwartz PJ, Moss AJ, Priori SG, Wang Q, Lehmann MH, Timothy K, Denjoy I, HaverkampW, Guicheney P, Paganini V, ScheinmanMM, Karnes PS. Gene-specific influence on the triggers for cardiac arrest in the long QT syndrome. Circulation 1997; 96(Suppl I): 1-204.
28. Dausse E, Berthet M, Denjoy I, Andre-Fouet X, Cruaud C, Bennaceur M, Faure S, Coumel P, Schwartz K, Guicheney P. A mutation in HERG associated with notched T waves in long QT syndrome. J Mol Cell Cardiol 1996;28: 1609-1615.
29. Matsa E, Dixon JE, Medway C, Georgiou O, Patel MJ, Morgan K, Kemp PJ, Staniforth A, Mellor I, Denning C. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J 2013. doi: 10.1093/eurherat/eht067.
30. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setala K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012;5: 220-230.
31. Sorimachi H, Ono Y. Regulation and physiological roles of the calpain system inmuscular disorders. Cardiovasc Res 2012;96: 11-22.
32. Goncalves I, Nitulescu M, Saido TC, Dias N, Pedro LM, José Fernandes EF, Ares MP, Porn-Ares I. Activation of calpain-1 in human carotid artery atherosclerotic lesions. BMC Cardiovasc Disord 2009;9: 26.
33. Gill C, Mestril R, Samali A. Losing heart: The role of apoptosis in heart disease-a novel therapeutic target? FASEB J 2002;16: 135-146.
34. Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-vanOostwaard D, Tertoolen LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J 2013;32: 3161-3175.
35. Iwai C, Li P, KurataY, HoshikawaY, Morikawa K, Maharani N, HigakiK, SasanoT, NotsuT, Ishido Y, Miake J, Yamamoto Y, Shirayoshi Y, Ninomiya H, Nakai A, Murata S, Yoshida A, Yamamoto K, Hiraoka M, Hisatome I. Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins. Cardiovasc Res 2013;100: 520-528.
36. Leu JI, Pimkina J, Frank A, Murphy ME, George DL.Asmall molecule inhibitor of inducible heat shock protein. Mol Cell 2009;36: 15-27.